Risk of ischaemic stroke in thyrotoxic atrial fibrillation.
Adolescent
Adult
Aged
Atrial Fibrillation
/ epidemiology
Brain Ischemia
/ epidemiology
Case-Control Studies
Female
Hemorrhage
/ epidemiology
Humans
Incidence
Male
Middle Aged
Retrospective Studies
Risk Factors
Severity of Illness Index
Stroke
/ epidemiology
Thyrotoxicosis
/ complications
Young Adult
Atrial fibrillation
stroke
thyrotoxicosis
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
01
04
2019
revised:
09
07
2019
accepted:
10
07
2019
pubmed:
14
7
2019
medline:
15
9
2020
entrez:
14
7
2019
Statut:
ppublish
Résumé
Atrial fibrillation (AF) is the most common cardiac complication of thyrotoxicosis and is strongly implicated in thromboembolic events. However, the incidence of stroke in thyrotoxic AF remains unclear. Herein, we aimed to investigate the risks of mortality and ischaemic stroke between patients with thyrotoxic AF and nonthyrotoxic AF. From Taiwan's National Health Insurance Research Database, 1868 patients with the concomitant diagnoses of AF and thyrotoxicosis identified between 2001 and 2010 were compared to 7472 patients with nonthyrotoxic AF using propensity score matching for age, sex and comorbidities. There was no significant difference in either CHA Patients with thyrotoxicosis and AF have a lower risk of stroke than patients with nonthyrotoxic AF. Treatment for thyrotoxicosis is also crucial as the prescription of anticoagulants based on CHA2DS2-VASc scores.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
561-570Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44:3103-3108.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071-2104.
Baber U, Howard VJ, Halperin JL, et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for geographic and racial differences in stroke (REGARDS) study. Circ Arrhythm Electrophysiol. 2011;4:26-32.
Chiang C-E, Naditch-Brûlé L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5:632-639.
Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482.
Traube E, Coplan NL. Embolic risk in atrial fibrillation that arises from hyperthyroidism: review of the medical literature. Tex Heart Inst J. 2011;38:225-228.
Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res. 2009;2:4.
Erem C, Kavgaci H, Ersoz HO, et al. Blood coagulation and fibrinolytic activity in hypothyroidism. Int J Clin Pract. 2003;57:78-81.
Ordookhani A, Burman KD. Hemostasis in overt and subclinical hyperthyroidism. Int J Endocrinol Metabol. 2017;15:e44157.
Yuen RW, Gutteridge DH, Thompson PL, Robinson JS. Embolism in thyrotoxic atrial fibrillation. Med J Aust. 1979;1:630-631.
Chen Q, Yan Y, Zhang L, Cheng K, Liu Y, Zhu W. Effect of hyperthyroidism on the hypercoagulable state and thromboembolic events in patients with atrial fibrillation. Cardiology. 2014;127:176-182.
Chan P-H, Hai J, Yeung C-Y, et al. Benefit of Anticoagulation therapy in hyperthyroidism-related atrial fibrillation. Clin Cardiol. 2015;38:476-482.
Busenbark LA, Cushnie SA. Effect of Graves' disease and methimazole on warfarin anticoagulation. Ann Pharmacothe. 2006;40:1200-1203.
Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20:236-242.
Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial infarction cases in the National Health Insurance Research Database in Taiwan. J Epidemiol. 2014;24:500-507.
Chao TF, Lip GY, Liu CJ, et al. Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation: a nationwide cohort study. Stroke. 2016;47:2462-2469.
Parsons LS. Performing a 1: N case-control match on propensity score. (2004). In Proceedings of the 29th Annual SAS users group international conference (pp. 165-29). SAS Institute.
Sheu JJ, Kang JH, Lin HC, Lin HC. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke. 2010;41:961-966.
Osuna PM, Udovcic M, Sharma MD. Hyperthyroidism and the heart. Methodist DeBakey Cardiovasc J. 2017;13:60-63.
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500-1510.
Poulin MF, Doukky R. Hyperthyroid atrial fibrillation: does it matter for stroke risk? Cardiology. 2014;128:51-53.
Okosieme OE, Taylor PN, Evans C, et al. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol. 2019;7:278-287.
Camm AJ, Savelieva I. Female gender as a risk factor for stroke associated with atrial fibrillation. Eur Heart J. 2017;38:1480-1484.